| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 02/24/2004 | US6696495 Treatment of disorders secondary to organic impairments |
| 02/24/2004 | US6696481 Immediate-release tablets; treatment of arterial hypertension and heart failure |
| 02/24/2004 | US6696479 Crystalline forms |
| 02/24/2004 | US6696478 Compound targeted to protein kinase c enzyme |
| 02/24/2004 | US6696476 Pyranoindazoles and their use for the treatment of glaucoma |
| 02/24/2004 | US6696471 Aminopyrrole compounds |
| 02/24/2004 | US6696470 Pyridylthiophene compounds |
| 02/24/2004 | US6696468 (s)-4-amino-5-chloro-2-methoxy-n-[1-[1-(2-tetrahydrofuryl-carbonyl)-4-piperidinylmethyl]-4-piperidinyl]benzamide, process for the preparation thereof, pharmaceutical composition containing the same, and intermediate therefor |
| 02/24/2004 | US6696467 Quinoline derivatives |
| 02/24/2004 | US6696464 Triazolo-pyridines anti-inflammatory compounds |
| 02/24/2004 | US6696458 Having x-ray powder diffraction pattern with lines at degrees 2 theta values 6.7, 12.5, 14.0 and 23.9 for cu k alpha radiation of wavelength 1.5406 angstrom |
| 02/24/2004 | US6696457 Morphinoid compounds |
| 02/24/2004 | US6696454 Inhibitors of spermidine synthase for the treatment of osteoarthritis and cartilage rehabilitation |
| 02/24/2004 | US6696453 Use of NF-κB inhibitors to treat dry eye disorders |
| 02/24/2004 | US6696452 Glycogen synthase kinase-3 and aurora-2 a serine/threonine protein kinase inhibitors; antidiabetic and anticancer agents and alzheimer's disease treatments |
| 02/24/2004 | US6696449 Control degradation of conencting tissue; cardiovascular disorders |
| 02/24/2004 | US6696446 Benzoylpyridazines, their preparation and use |
| 02/24/2004 | US6696445 Neuropeptide y receptor antagonists comprising heterocyclic nitrogen compounds and/or prodrugs used for prophylaxis of eating and cardiovascular disorders |
| 02/24/2004 | US6696444 Neurotransmitter antagonists comprising compounds such as 4,2'-difluoro-5'-(3-(1-fluoro-1-methylethyl)imidazo(1,2-b)(1,2 ,4) triazin-7-yl)biphenyl-2-carbonitrile, administered for the prophylaxis of headaches or as anticonvulsants |
| 02/24/2004 | US6696442 Carbocyclic and heterocyclic substituted semicarbazones and thiosemicarbazones and the use thereof |
| 02/24/2004 | US6696437 Polymerase inhibitors comprising heterocyclic amides such as 2-pyridin-2-ylbenzimidazole-4-carboxamide, used for prophylaxis of neurodegenerative disorders, damage to hearts or brains, and as anticarcinogenic agents |
| 02/24/2004 | US6696434 Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases |
| 02/24/2004 | US6696428 Use of dopamine receptor antagonists in palliative tumor therapy |
| 02/24/2004 | US6696414 Use of growth hormone in low dose |
| 02/24/2004 | US6696408 Administering glycosylated polypeptides as antiepileptics and anticonvulsants or for prophylaxis of psychological disorders |
| 02/24/2004 | US6696263 PCNA associated cell cycle proteins, compositions and methods of use |
| 02/24/2004 | US6696088 Useful for decreasing the potential for abuse of the opioid agonist contained therein; for use in therapy of pain |
| 02/24/2004 | US6696079 Delivery and activation through liposome incorporation of diaminocyclohexane platinum(II) complexes |
| 02/24/2004 | US6696072 Mixture of phentolamine mesylate, papaverine hydrochloride, and alprostadil in buffer containing l-arginine and glycine injected into penis |
| 02/24/2004 | US6696066 Opioid agonist/antagonist combinations |
| 02/24/2004 | US6696060 Methods for sterilizing preparations of monoclonal immunoglobulins |
| 02/24/2004 | US6696039 Amyloid plaque aggregation inhibitors and diagnostic imaging agents |
| 02/24/2004 | CA2293461C Alkyl-4-silylheterocyclic phenols and thiophenols as antioxidant agents |
| 02/24/2004 | CA2219081C Angiostatin fragments and aggregate angiostatin and methods of use |
| 02/24/2004 | CA2114542C Benzimidazolone derivatives as 5-ht1a and 5-ht2 antagonists |
| 02/23/2004 | CA2399630A1 Scyphostatin analogues as smase inhibitors |
| 02/21/2004 | CA2437664A1 Anti-aging/menopause symptoms relief using ganoderma lucidum spores |
| 02/19/2004 | WO2004015109A1 Human acid sensing ion channel 2b (hasic2b), process for producing the same, and its use |
| 02/19/2004 | WO2004015103A1 Akt2-BINDING PROTEIN |
| 02/19/2004 | WO2004015100A1 Method of judging inflammatory disease |
| 02/19/2004 | WO2004015072A2 Mrbs as modifiers of the rb pathway and methods of use |
| 02/19/2004 | WO2004014932A1 Pyrazole derivative, medicinal composition containing the same, medicinal use thereof, and intermediate for production thereof |
| 02/19/2004 | WO2004014931A1 ARYL 5-THIO-β-D-GLUCOPYRANOSIDE DERIVATIVES AND REMEDIES FOR DIABETES CONTAINING THE SAME |
| 02/19/2004 | WO2004014930A1 PROCESS FOR SELECTIVE PRODUCTION OF ARYL 5-THIO-β-D- ALDOHEXOPYRANOSIDES |
| 02/19/2004 | WO2004014929A1 Derivatives of monosaccharides for drug discovery |
| 02/19/2004 | WO2004014920A1 Bicyclic heteroaromatic compounds as kinase inhibitors |
| 02/19/2004 | WO2004014917A2 Antitumoral analogs of lamellarins |
| 02/19/2004 | WO2004014915A1 Novel derivatives of cycloalcanodiones, method for the production thereof and their pharmacological applications |
| 02/19/2004 | WO2004014913A2 Derivatives of 2-trifluormethyl-6-aminopurine as phosphodiesterase 4 inhibitors |
| 02/19/2004 | WO2004014911A1 Phosphodiesterase 4 inhibitors |
| 02/19/2004 | WO2004014910A1 Dihydropyrazolopyridine compounds |
| 02/19/2004 | WO2004014905A1 Substituted benzimidazole compounds |
| 02/19/2004 | WO2004014903A1 2-(3-aminoaryl)amino-4-aryl-thiazoles and their use as c-kit inhibitors |
| 02/19/2004 | WO2004014894A1 Novel prodrugs of 1-methyl-2(4-amidinophenylaminomethyl)-benzimidazol-5-yl-carboxylic acid-(n-2-pyridil-n-2-hydroxycarbonylethyl)-amide, production and use thereof as medicaments |
| 02/19/2004 | WO2004014875A1 Crystal forms of quinoxaline-2-carboxylic acid [4-carbamoyl-1-(3-fluorobenzyl)-2,7-dihydroxy-7-methyl-octyl]-amide |
| 02/19/2004 | WO2004014873A1 4-substituted quinazoline-8-carboxyamide derivative and pharmaceutically acceptable addition salt thereof |
| 02/19/2004 | WO2004014861A1 4-substituted-quinoline-8-carboxylic amide derivatives and pharmacologically acceptable addition salts thereof |
| 02/19/2004 | WO2004014856A1 2,3-dihydro-isoindol-1-ones with mao-b inhibiting activity |
| 02/19/2004 | WO2004014851A2 Tyrosine kinase inhibitors |
| 02/19/2004 | WO2004014847A1 Mcp-1 receptor antagonists and method of use thereof |
| 02/19/2004 | WO2004014844A2 Aryl and heteroaryl compounds and methods to modulate coagulation |
| 02/19/2004 | WO2004014843A1 Substituted amino compounds and use thereof |
| 02/19/2004 | WO2004014825A1 Cannabinoid receptor ligands |
| 02/19/2004 | WO2004014433A1 Inhibition of proliferation and infiltration of brain tumor cells caused by expression of ampa-type glutamate receptor subunit |
| 02/19/2004 | WO2004014430A1 Compositions of a cyclooxygenase-2 selective inhibitor and a carbonic anhydrase inhibitor for the treatment of neoplasia |
| 02/19/2004 | WO2004014429A1 Regulator for mental disease risk fragility |
| 02/19/2004 | WO2004014428A1 Remedy for intestinal diseases and visceral pain |
| 02/19/2004 | WO2004014415A1 Growth hormone releasing peptides |
| 02/19/2004 | WO2004014412A1 Myocardial cell protecting agents |
| 02/19/2004 | WO2004014407A1 Remedy |
| 02/19/2004 | WO2004014405A1 Use of ginkgo biloba extracts in order to promote muscle mass to the detriment of fatty mass |
| 02/19/2004 | WO2004014395A1 Female hormone-containing patch |
| 02/19/2004 | WO2004014386A1 Therapeutic combinations of erb b kinase inhibitors and antineoplastic therapies |
| 02/19/2004 | WO2004014374A1 Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
| 02/19/2004 | WO2004014369A1 Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals |
| 02/19/2004 | WO2004014367A2 Use of an amyloid beta vaccination in combination with a selective cox-2 inhibitor for the treatment of alzheimer's disease |
| 02/19/2004 | WO2004014352A2 Methods for treating carbonic anhydrase mediated disorders |
| 02/19/2004 | WO2004014311A2 Nogo receptor antagonists |
| 02/19/2004 | WO2004014304A2 Electrospun amorphous pharmaceutical compositions |
| 02/19/2004 | WO2004014301A2 PSMCs AS MODIFIERS OF THE RB PATHWAY AND METHODS OF USE |
| 02/19/2004 | WO2004014147A1 Method for controlling hairballs |
| 02/19/2004 | WO2004007726A3 Brachyspira hyodysenteriae vaccine |
| 02/19/2004 | WO2004007481A3 Substituted amine derivatives and methods of use in the treatment of angiogenesis relates disorders |
| 02/19/2004 | WO2004007478A3 Derivatives of 3-guanidinocarbonyl-1-heteroaryl-pyrrole, process for their preparation and their pharmaceutical use |
| 02/19/2004 | WO2004007430A3 Benzamide or phenylacetamide derivatives useful as thyroid receptor ligands |
| 02/19/2004 | WO2004000840A3 Quinuclidine derivatives and pharmaceutical compositions containing the same |
| 02/19/2004 | WO2003101995A3 Camptothecins with a modified lactone ring |
| 02/19/2004 | WO2003097852A3 Assay for identifying inhibitors of fc gamma riii signaling |
| 02/19/2004 | WO2003087318A3 Truncated 24 kda basic fibroblast growth factor |
| 02/19/2004 | WO2003086306A3 5ht2c receptor modulators |
| 02/19/2004 | WO2003082190A3 Spirocyclic amides as cannabinoid receptor modulators |
| 02/19/2004 | WO2003075850A9 Methods for alzheimer's disease treatment and cognitive enhancement |
| 02/19/2004 | WO2003070188A3 Method of treating trx mediated diseases |
| 02/19/2004 | WO2003065989A3 (oxime)carbamoyl fatty acid amide hydrolase inhibitors |
| 02/19/2004 | WO2003065988A3 A combination for treating cold and cough |
| 02/19/2004 | WO2003065046A3 Diagnostics and therapeutics for diseases associated with a new human 5-ht6 receptor |
| 02/19/2004 | WO2003053474A3 Use of micro-organisms for a directed delivery of substances to specific parts of the gut |
| 02/19/2004 | WO2003049593A3 Prevention of flap necrosis in plastic surgery |
| 02/19/2004 | WO2003045974A3 Methods and compositions for derepression of iap-inhibited caspase |
| 02/19/2004 | WO2003037168A3 Methods and formulations for minimizing spasticity in blood vessel grafts |